Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00850122 | An Open Label Study to Describe the Pharmacokinetics of Cefazolin in Preterm Neonates | PHASE1 | COMPLETED | 9 | — | — | Jul 1, 2013 | Jul 1, 2018 | Sep 4, 2018 | 1 | Brazil |
| Arm | Type | Description |
|---|---|---|
| Cefazolin | EXPERIMENTAL | Dosage Number of Infants ≤28 days of age 25 mg/kg IV q12 6 29-120 days of age 25 mg/kg IV q8 6 |
| Name | Type | Description |
|---|---|---|
| cefazolin | DRUG | Cefazolin dosing - administered for 48 hours Dosage ≤28 days of age 25 mg/kg IV q12 29-120 days of age 25 mg/kg IV q8 |
Inclusion Criteria: * \< 28 weeks gestation at birth * \> 48 hours and \<121 days of age at the time of study drug administration * One of the following: * Suspected systemic infection * Receiving cefazolin for prophylaxis * Receiving cefazolin treatment of a systemic infection Exclusion Cr...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| AstraZeneca PLC | AZN | 1 | PHASE2 | AZD4144 |
| ImmunityBio Inc | IBRX | 1 | PHASE2 | Nogapendekin alfa inbakicept |
| Bluejay Diagnostics, Inc. | BJDX | 2 | — | Undisclosed |
| CytoSorbents Corporation | CTSO | 1 | — | Undisclosed |
| Danaher Corporation | DHR | 3 | — | Undisclosed |
| Spectral AI, Inc. Class A | MDAI | 1 | NA | Undisclosed |